Symbols / TELO $1.34 +1.52%
TELO Chart
About
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 46.07M |
| Enterprise Value | 38.83M | Income | -11.25M | Sales | — |
| Book/sh | 0.21 | Cash/sh | 0.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.79 | PEG | — |
| P/S | — | P/B | 6.50 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 17.34 |
| Current Ratio | 17.51 | Debt/Eq | 1.34 | LT Debt/Eq | — |
| EPS (ttm) | -0.37 | EPS next Y | -0.28 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 16:00 | ROA | -167.42% |
| ROE | -3.03% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 34.38M |
| Shs Float | 19.03M | Short Float | 6.92% | Short Ratio | 10.64 |
| Short Interest | — | 52W High | 4.80 | 52W Low | 1.05 |
| Beta | -0.65 | Avg Volume | 149.83K | Volume | 53.73K |
| Target Price | — | Recom | None | Prev Close | $1.32 |
| Price | $1.34 | Change | 1.52% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.34
Latest analyst target
3. DCF / Fair value
$0.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.34
Low
—
High
—
Mean
—
- Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan Mon, 05 Jan 2026 08
- TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI hu, 05 Mar 2026 14
- Rodman & Renshaw initiates Telomir Pharma stock with Buy rating - Investing.com ue, 13 Jan 2026 08
- Telomir Sets Vote on Transformative TELI Merger and Governance Changes - TipRanks hu, 19 Feb 2026 08
- Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 09 Oct 2025 14
- TELO Rises on Promising Telomir-1 Preclinical Results - Yahoo Finance Fri, 13 Jun 2025 07
- Why Is Telomir Pharmaceuticals Stock Trading Higher Today? - Telomir Pharmaceuticals (NASDAQ:TELO) - Benzinga hu, 09 Oct 2025 07
- Telomir Pharma (NASDAQ: TELO) Telomir-1 Shows Preclinical HL60 Leukemia Activity - Stock Titan Fri, 21 Nov 2025 08
- Telo Genomics increases convertible debenture offering to $1.6M - Investing.com Fri, 27 Feb 2026 08
- Will Telomir Pharmaceuticals Bounce Back? - StocksToTrade Fri, 21 Nov 2025 08
- EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND - Yahoo Finance Wed, 21 May 2025 07
- Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results - TipRanks Wed, 17 Dec 2025 08
- McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday - Benzinga ue, 07 Oct 2025 07
- Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - Stock Titan hu, 05 Feb 2026 08
- Telomir stock soars after tumor suppressor gene reactivation results - Investing.com ue, 07 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 400 | 2442 | — | Sale at price 6.01 - 6.20 per share. | AMINOV EREZ | Chief Executive Officer | — | 2024-08-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.19M | -3.94M | -854.15K | -138.13K |
| TotalUnusualItems | 0.00 | -7.49M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -7.49M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.53M | -13.07M | -854.15K | -138.13K |
| EBITDA | -12.19M | -11.43M | -854.15K | -138.13K |
| EBIT | -12.19M | -11.43M | -854.15K | -138.13K |
| NetInterestIncome | -4.29M | -1.64M | 0.00 | |
| InterestExpense | 4.34M | 1.64M | 0.00 | |
| InterestIncome | 48.00K | 0.00 | ||
| NormalizedIncome | -16.53M | -5.59M | -854.15K | -138.13K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.53M | -13.07M | -854.15K | -138.13K |
| TotalExpenses | 12.24M | 3.94M | 854.15K | 138.13K |
| DilutedAverageShares | 29.54M | 29.61M | 29.61M | 29.61M |
| BasicAverageShares | 29.54M | 29.61M | 29.61M | 29.61M |
| DilutedEPS | -0.56 | -0.44 | -0.03 | -0.00 |
| BasicEPS | -0.56 | -0.44 | -0.03 | -0.00 |
| DilutedNIAvailtoComStockholders | -16.53M | -13.07M | -854.15K | -138.13K |
| NetIncomeCommonStockholders | -16.53M | -13.07M | -854.15K | -138.13K |
| NetIncome | -16.53M | -13.07M | -854.15K | -138.13K |
| NetIncomeIncludingNoncontrollingInterests | -16.53M | -13.07M | -854.15K | -138.13K |
| NetIncomeContinuousOperations | -16.53M | -13.07M | -854.15K | -138.13K |
| PretaxIncome | -16.53M | -13.07M | -854.15K | -138.13K |
| OtherIncomeExpense | -7.49M | |||
| SpecialIncomeCharges | 0.00 | -7.49M | 0.00 | |
| OtherSpecialCharges | 7.49M | |||
| NetNonOperatingInterestIncomeExpense | -4.29M | -1.64M | 0.00 | |
| InterestExpenseNonOperating | 4.34M | 1.64M | 0.00 | |
| InterestIncomeNonOperating | 48.00K | 0.00 | ||
| OperatingIncome | -12.24M | -3.94M | -854.15K | -138.13K |
| OperatingExpense | 12.24M | 3.94M | 854.15K | 138.13K |
| OtherOperatingExpenses | 370.50K | 1.77M | ||
| ResearchAndDevelopment | 2.24M | 1.57M | 833.21K | 126.49K |
| SellingGeneralAndAdministration | 9.64M | 600.19K | 20.94K | 11.64K |
| GeneralAndAdministrativeExpense | 9.64M | 600.19K | 20.94K | 11.64K |
| OtherGandA | 9.64M | 600.19K | 20.94K | 11.64K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 29.76M | 29.61M | 29.61M | 29.61M |
| ShareIssued | 29.76M | 29.61M | 29.61M | 29.61M |
| NetDebt | 99.77K | |||
| TotalDebt | 101.00K | |||
| TangibleBookValue | 643.04K | 3.44M | -937.28K | -138.13K |
| InvestedCapital | 643.04K | 3.54M | -937.28K | -138.13K |
| WorkingCapital | 643.04K | -900.34K | -937.28K | -138.13K |
| NetTangibleAssets | 643.04K | 3.44M | -937.28K | -138.13K |
| CommonStockEquity | 643.04K | 3.44M | -937.28K | -138.13K |
| TotalCapitalization | 643.04K | 3.44M | -937.28K | -138.13K |
| TotalEquityGrossMinorityInterest | 643.04K | 3.44M | -937.28K | -138.13K |
| StockholdersEquity | 643.04K | 3.44M | -937.28K | -138.13K |
| OtherEquityInterest | -55.00K | |||
| RetainedEarnings | -30.60M | -14.06M | -992.28K | -138.13K |
| AdditionalPaidInCapital | 31.24M | 17.50M | 55.00K | 55.00K |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 680.97K | 1.34M | 986.01K | 138.13K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 680.97K | 1.34M | 986.01K | 138.13K |
| CurrentDebtAndCapitalLeaseObligation | 101.00K | |||
| CurrentDebt | 101.00K | |||
| LineOfCredit | 0.00 | 101.00K | 0.00 | |
| PayablesAndAccruedExpenses | 680.97K | 1.23M | 986.01K | 138.13K |
| Payables | 680.97K | 1.23M | 986.01K | 138.13K |
| DuetoRelatedPartiesCurrent | 93.43K | 527.38K | 581.79K | 119.40K |
| AccountsPayable | 587.54K | 707.19K | 404.22K | 18.73K |
| TotalAssets | 1.32M | 4.77M | 48.73K | 0.00 |
| TotalNonCurrentAssets | 0.00 | 4.34M | 0.00 | 0.00 |
| NonCurrentDeferredAssets | 0.00 | 4.34M | 0.00 | |
| CurrentAssets | 1.32M | 435.23K | 48.73K | 0.00 |
| CurrentDeferredAssets | 0.00 | 303.28K | 47.31K | 0.00 |
| PrepaidAssets | 57.87K | 713.00 | 0.00 | |
| Receivables | 0.00 | 130.00K | 0.00 | |
| DuefromRelatedPartiesCurrent | 0.00 | 130.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 1.27M | 1.23K | 1.42K | 0.00 |
| CashAndCashEquivalents | 1.27M | 1.23K | 1.42K | 0.00 |
| CashFinancial | 1.27M | 1.23K | 1.42K | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.07M | -3.86M | -468.66K | -119.40K |
| RepaymentOfDebt | -101.00K | 0.00 | ||
| IssuanceOfDebt | 0.00 | 1.45M | 462.39K | |
| IssuanceOfCapitalStock | 6.83M | 1.00M | 0.00 | 0.00 |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 1.27M | 1.23K | 1.42K | 0.00 |
| BeginningCashPosition | 1.23K | 1.42K | 0.00 | 0.00 |
| ChangesInCash | 1.26M | -188.00 | 1.42K | |
| FinancingCashFlow | 6.34M | 3.86M | 470.08K | 119.40K |
| CashFlowFromContinuingFinancingActivities | 6.34M | 3.86M | 470.08K | 119.40K |
| NetOtherFinancingCharges | -433.94K | 1.41M | 7.69K | 119.40K |
| ProceedsFromStockOptionExercised | 37.30K | 0.00 | ||
| NetCommonStockIssuance | 6.83M | 1.00M | 0.00 | 0.00 |
| CommonStockIssuance | 6.83M | 1.00M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -101.00K | 1.45M | 462.39K | |
| NetShortTermDebtIssuance | -101.00K | 1.45M | 462.39K | |
| ShortTermDebtPayments | -101.00K | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | 1.45M | 462.39K | |
| OperatingCashFlow | -5.07M | -3.86M | -468.66K | -119.40K |
| CashFlowFromContinuingOperatingActivities | -5.07M | -3.86M | -468.66K | -119.40K |
| ChangeInWorkingCapital | 126.47K | 113.84K | 385.49K | 18.73K |
| ChangeInPayablesAndAccruedExpense | 183.63K | 114.56K | 385.49K | 18.73K |
| ChangeInPrepaidAssets | -57.16K | -713.00 | 0.00 | |
| OtherNonCashItems | 4.47M | 1.61M | ||
| StockBasedCompensation | 6.87M | 0.00 | ||
| OperatingGainsLosses | 7.49M | |||
| NetIncomeFromContinuingOperations | -16.53M | -13.07M | -854.15K | -138.13K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TELO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|